FDA advisors unanimously recommend Moderna's COVID vaccine for 6 to 17-year olds
carmengabriela/iStock Editorial via Getty Images


A panel of U.S. FDA advisors voted unanimously Tuesday to recommend approval of Moderna's COVID-19 vaccine for children and adolescents between the ages of six and 17 years old.
Two separate votes were taken. One for six to 11-year-olds and the other for 12 to 17-year-olds. Both votes were 22-0 that the benefits of the vaccine outweighed the risks.

The FDA is not obligated to follow the recommendations of its advisory committees but usually does.
If the agency approves it in this age group, it would become the second COVID vaccine authorized in this age group, joining Pfizer (PFE)/BioNTech's (BNTX).
In briefing documents released ahead of the meeting, FDA researchers found two doses of the Moderna (NASDAQ:MRNA) achieved 93% efficacy in both age groups.
The Vaccines and Related Biologics Products Advisory Committee will meet again Wednesday to debate whether to recommend the Moderna (MRNA) vaccine in children six months to five years old.